A Phase Ib/II, Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Toripalimab Injection (JS001) as a Neoadjuvant Therapy for Patients With Resectable Hepatocellular Carcinoma (HCC) or Intrahepatic Cholangiocarcinoma (ICC)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Lenvatinib
Indications Cholangiocarcinoma; Liver cancer
Focus Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

24 Nov 2023 Status changed from recruiting to discontinued.Reason the study was stopped: Enrollment is over, the study was completed.
10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
25 Mar 2021 Planned number of patients changed from 20 to 40.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight